The US Food and Drug Administration (FDA) has introduced FDA PreCheck, a new programme to facilitate the construction of manufacturing sites.  More than half of pharmaceuticals distributed in the US are manufactured overseas and the US is reliant on overseas sources for active pharmaceutical ingredients (APIs).  “Our gradual overreliance on foreign drug manufacturing has created […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!